Conditions: Glaucoma, Primary Open Angle Ocular Hypertension
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1137
Healthy volunteers: no

Brief summary:
This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

Detailed description:

Arms:
arm 1: Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.

Interventions: intervention 1: Bimatoprost 0.01%
Intervention descriptions: intervention 1: Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.

Protocol document: